https://www.educationcannotwait.org/news-stories/directors-corner/brave-new-world
NEW YORK , Feb. 11, 2025 /PRNewswire/ -- The future of the human race hangs in the balance. With science and technology far outpacing the capacity of most humans to keep up, we must arm our future scientists and future leaders with the knowledge, skills and critical thinking abilities they need to survive and thrive in the brave new world of the 21st century.
To achieve these goals, we must empower an entire generation of girls in crises to receive the education, training and resources they need to improve their knowledge and skills base in Science, Technology, Engineering and Math (STEM).
Today, we celebrate the 10th Anniversary of the International Day of Women and Girls in Science, and recognize the groundbreaking work of leading women scientists throughout history such as Marie Curie, who pioneered research on radioactivity and was awarded two Nobel Prizes in Science.
Today, we also recognize the power and potential of an entire generation of future scientists. Brave leaders such as ECW Global Champion Somaya Faruqi, who led the Afghan Girls' Robotics Team in Kabul and built a ventilator out of car parts.
Together with ECW and our strategic partners, strong visionaries like them inspire our global charge to ensure girls have access to STEM education from an early age, and women can break through the glass ceiling to find their rightful place in universities, labs and research facilities across the globe.
It is not an easy road. For girls living on the frontlines of armed conflict, climate change and forced displacement, the thought of even attending school is elusive at best. In all, there are now nearly a quarter of a billion crisis-affected girls and boys whose right to a quality education fit for the 21st century is interrupted by these preventable protracted crises. Girls are among the most vulnerable. Rather than studying science or learning about technology, they are exposed to forced child marriage and unwanted pregnancies without their potentials ever being achieved.
It is possible to change all that. In Chad, through ECW investments delivered by UNICEF and partners, Khadidja is learning about science, math and mechanics in a classroom designed to provide non-formal education to children that have been impacted by the various crises facing the nation. Nadejda, a Ukrainian refugee in Moldova, is building up her digital skills and even learning to develop a website thanks to support at an ECW-funded EDUTech lab in her new school.
Technology, artificial intelligence and breakthroughs in science have the potential to save humanity from our collision course with our own demise. We need to train the young women – and young men – who will guide us through this technological transformation.
Our best investment is to ensure that every girl and boy on planet earth is able to access the quality education they need to bravely thrive in a world undergoing rapid transformation, and face it head on!
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
A Brave New World: International Day of Women and Girls in Science Statement by Education Cannot Wait Executive Director Yasmine Sherif
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
